约达米 | 440-58-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 约达米
• 中文别名: 碘达胺
• 英文名称: iodamide
• 英文别名: Uromiro；3-Acetylaminomethyl-5-acetylamino-2,4,6-triiodo-benzoesaeure；3-Acetylaminomethyl-5-acetylamino-2,4,6-trijod-benzoesaeure；5-Acetylamino-3-acetylaminomethyl-2,4,6-triiod-benzoesaeure；3-acetamido-5-(acetamidomethyl)-2,4,6-triiodobenzoic acid
• CAS: 440-58-4
• 化学式: C₁₂H₁₁I₃N₂O₄
• 分子量: 627.944
• InChiKey: VVDGWALACJEJKG-UHFFFAOYSA-N

物化性质

• 熔点：
  255-257°
• 沸点：
  683.4±55.0 °C(Predicted)
• 密度：
  2.3140 (estimate)
• 溶解度：
  0.00 M

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  约达米 、 溴代十六烷 生成 3-Acetylaminomethyl-5-acetylamino-2,4,6-trijod-benzoesaeure-cetylester
  参考文献：
  名称：

  Röntgenkontrastmittel. 6. Mitteilung. Jodierte Derivate der 3-Aminomethyl-benzoesäure

  摘要：

  AbstractA number of mono‐ and of diacylated 3‐aminomethyl‐5‐amino‐2,4,6‐triiodobenzoic acids have been synthesized for evaluation as X‐ray contrast agents. 3‐Acetamidomethyl‐5‐acetamido‐2,4,6‐triiodobenzoic acid seems to be a promising urographic agent [1].

  DOI：

  10.1002/hlca.19650480126

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Fluorinated carbohydrate conjugates
  申请人：McBride J. William

  公开号：US20050136001A1

  公开（公告）日：2005-06-23

  Disclosed are novel conjugates that include fluorinated carbohydrate molecules and methods for synthesizing the conjugates. The fluorinated carbohydrate molecule may include a radioisotope. The method of synthesizing the conjugate is useful for labeling selected molecules, and the conjugates may be useful in diagnostic or therapeutic methods. Particularly, the conjugates may be useful in diagnostic or therapeutic kits.

  本文披露了包括氟化碳水化合物分子的新型共轭物以及合成这些共轭物的方法。氟化碳水化合物分子可能包括放射性同位素。合成共轭物的方法可用于标记选择的分子，这些共轭物可能在诊断或治疗方法中有用。特别是，这些共轭物可能在诊断或治疗试剂盒中有用。